Table 3.
Change in various parameter after 6 months of treatment in vitamin D + SMT and SMT groups
| Paired difference | |||||
|---|---|---|---|---|---|
| Characteristic | Baseline (mean ± SD) | At 6 months (mean ± SD) | Mean ± SD | t‐Value | P‐value |
| BMI (kg/m2) | |||||
| SMT + vitamin D (n = 51) | 28.9 ± 6.5 | 28.4 ± 6.3 | 0.54 ± 1.4 | 2.7 | 0.09 |
| SMT (n = 30) | 27.4 ± 4.0 | 27.1 ± 4.4 | 0.37 ± 1.5 | 1.3 | 0.791 |
| Fasting blood sugar (mg/dL) | |||||
| SMT + vitamin D (n = 51) | 100.7 ± 16 | 100.1 ± 9 | 0.58 ± 11.7 | 0.35 | 0.723 |
| SMT (n = 30) | 102 ± 27 | 99 ± 8 | 3.35 ± 21 | 0.84 | 0.406 |
| ALT (IU/mL) | |||||
| SMT + vitamin D (n = 51) | 87 ± 48 | 59 ± 32 | 27.85 ± 49.8 | 3.99 | <0.001 |
| SMT (n = 30) | 64 ± 35 | 62 ± 24 | 2.44 ± 34.9 | 0.38 | 0.704 |
| Insulin levels (mU/L) | |||||
| SMT + vitamin D (n = 51) | 11 ± 8.7 | 10 ± 7.9 | 0.5 ± 2.3 | 1.52 | 0.135 |
| SMT(n = 30) | 7.2 ± 5 | 8.7 ± 6.5 | 1.49 ± 2.8 | 2.91 | 0.007 |
| HOMA‐IR | |||||
| SMT + vitamin D (n = 51) | 2.7 ± 2.1 | 2.6 ± 2.04 | 0.11 ± 0.5 | 1.42 | 0.162 |
| SMT (n = 30) | 1.8 ± 1.6 | 2.2 ± 1.8 | 1.49 ± 2.8 | 2.91 | 0.007 |
| TNF‐α (pg/mL) | |||||
| SMT + vitamin D (n = 51) | 250 ± 181 | 228 ± 184 | 22.07 ± 112.2 | 1.40 | 0.166 |
| Adiponectin (pg/mL) | |||||
| SMT + vitamin D (n = 51) | 836 ± 309 | 908 ± 312 | 71.09 ± 206.6 | 2.45 | 0.018 |
ALT, alanine aminotransferase; BMI, body mass index; HOMA‐IR, homeostasis model assessment‐insulin resistance; SMT, standard medical treatment; TNF‐α, tumor necrosis factor‐α.